Antitrust Antitrust

US FTC’s Section 13(b) powers must be restored to tackle anticompetitive drug pricing practices, senators told

By Khushita Vasant
  • 05 May 2022 23:19
  • 06 May 2022 00:25
The Federal Trade Commission must act to combat anticompetitive drug pricing practices by pharmacy benefit managers in the US, senators were told today. Congress also must pass laws that restore the agency’s powers to collect monetary redress for consumers, experts testified at a commerce committee panel hearing.
The Subcommittee on

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Khushita Vasant

Chief Antitrust Correspondent, US

Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News